TC BioPharm Ltd - נכסים נקיים למניה בודדת TCBP

Geopolitical sanctions and logistical disruptions between Britain and the rest of the world are slowing the development of anti-cancer agents. The GURU.Markets platform features this chart of the book value per common share for TC Biopharm (TCBP), where 2.00 indicates the current level. TC Biopharm (TCBP) is developing patent-protected T-cell therapy against leukemia while awaiting FDA data, maintaining key immunologists through a system of stock options and grants.

TC Biopharm focuses on protecting its R&D competencies in cell therapy by retaining key immunologists. The book value per share measures the business's net assets, allowing investors to assess the company's asset base; meanwhile, the horizontal trend of the book value per share indicates stagnant accumulated capital and a temporary lull in the company's operational expansion.